United Therapeutics Corp
UTHR
$0.00
-0.96%
United Therapeutics Corp is a biotechnology company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH). It is a leader in the PAH treatment space, with a core advantage built around its deep expertise in the prostacyclin pathway and its portfolio of treprostinil-based products.…
UTHR
United Therapeutics Corp
$0.00
Related headlines
Investment Opinion: Should I buy UTHR Today?
Based on a synthesis of the provided data, the objective assessment for United Therapeutics (UTHR) is a Hold. The company's outstanding financial health, profitability, and positive clinical catalyst provide a solid foundation. However, the stock's dramatic recent appreciation and premium valuation multiples suggest the current price may fully reflect this near-term optimism. New investors may want to wait for a more attractive entry point or clearer evidence of sustained commercial execution from the new Tyvaso indication before establishing a position.
Sign up to view all
UTHR 12-Month Price Forecast
The analysis is neutral due to the tension between superb fundamentals/catalysts and a price that appears to discount near-term success. Confidence is medium as the 12-month path is highly dependent on a single regulatory event (Tyvaso) whose outcome is binary and timing uncertain.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on United Therapeutics Corp's 12-month outlook, with a consensus price target around $0.00 and implied upside of — versus the current price.
Average Target
$0.00
5 analysts
Implied Upside
—
vs. current price
Analyst Count
5
covering this stock
Price Range
$0 - $0
Analyst target range
Wall Street analyst coverage for United Therapeutics is active, with recent ratings from multiple firms. In the past few months, institutions including TD Cowen, UBS, RBC Capital, HC Wainwright & Co., and Oppenheimer have maintained "Buy" or "Outperform" ratings. Wells Fargo has maintained an "Equal Weight" rating. The consensus appears positive, driven by catalysts such as positive Phase 3 data for Tyvaso in a new indication. Specific consensus target price and ratings distribution data are not available in the provided inputs.
Bulls vs Bears: UTHR Investment Factors
United Therapeutics presents a compelling mix of strong fundamentals and promising catalysts against a backdrop of high valuation and execution risk. The company's debt-free balance sheet, exceptional margins, and recent positive clinical data are powerful bullish drivers. However, the stock's significant run-up and premium multiples suggest much of the near-term optimism may already be priced in.
Bullish
- Strong Financial Health: Zero long-term debt, high current ratio of 6.6, and robust free cash flow of $1.04B.
- Exceptional Profitability: High net income margin of 46.1% and gross margin of 86.9% in Q4 2025.
- Positive Clinical Catalyst: Positive Phase 3 data for Tyvaso in new lung disease, driving recent stock surge.
- Strong Momentum & Outperformance: Stock up 17.7% in one month, significantly outperforming the S&P 500.
Bearish
- High Valuation Multiples: P/E of 16.2, P/S of 6.8, and EV/EBITDA of 11.0 may limit upside.
- Revenue Concentration Risk: Majority of revenue from Tyvaso DPI and the U.S. market.
- Elevated Short Interest: Short ratio of 5.64 indicates significant bearish sentiment.
- Price Near 52-Week High: Trading just 2.5% below 52-week high of $607.89, suggesting limited near-term upside.
UTHR Technical Analysis
The stock has demonstrated a strong overall uptrend over the past six months, with the price rising from approximately $443 in early October 2025 to close at $592.98 on March 31, 2026, representing a 33.7% gain. This bullish trend has been punctuated by significant volatility, including a sharp spike from the $470s to over $535 on February 25, 2026, and another major jump from $522 to $588 on March 30, 2026. Short-term performance has been exceptionally strong, with the stock up 17.68% over the past month, significantly outperforming the S&P 500, which was down 5.25% over the same period. The three-month performance is also robust at a 21.7% gain, again far exceeding the broader market's decline of 4.63%. The stock's current price of $592.98 is near the top of its 52-week range of $266.98 to $607.89, trading just 2.5% below its 52-week high. This positioning indicates strong momentum and suggests the stock is testing a key resistance level.
Beta
0.75
0.75x market volatility
Max Drawdown
-16.4%
Largest decline past year
52-Week Range
$267-$608
Price range past year
Annual Return
+80.9%
Cumulative gain past year
| Period | UTHR Return | S&P 500 |
|---|---|---|
| 1m | +13.3% | -4.3% |
| 3m | +13.7% | -4.0% |
| 6m | +24.7% | -2.0% |
| 1y | +80.9% | +22.2% |
| ytd | +13.7% | -3.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
UTHR Fundamental Analysis
Revenue growth has been steady, with Q4 2025 revenue of $790.2 million representing a 7.4% year-over-year increase from Q4 2024. Profitability remains robust, with a net income margin of 46.1% in the latest quarter, supported by a high gross margin of 86.9%. The company exhibits exceptional financial health, with a debt-to-equity ratio of 0, indicating no long-term debt, and a very strong current ratio of 6.6. Cash flow generation is solid, with trailing twelve-month free cash flow reported at $1.04 billion. Operational efficiency metrics are strong, with a Return on Equity (ROE) of 18.8% and a Return on Assets (ROA) of 12.4%, reflecting effective use of shareholder capital and company assets to generate profits.
Quarterly Revenue
$790200000.0B
2025-12
Revenue YoY Growth
+0.07%
YoY Comparison
Gross Margin
+0.86%
Latest Quarter
Free Cash Flow
$1.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is UTHR Overvalued?
Given the company's substantial positive net income, the primary valuation metric is the Price-to-Earnings (P/E) ratio. The trailing P/E ratio is 16.2, while the forward P/E is 17.4, based on the provided data. The Price-to-Sales (P/S) ratio is 6.8, and the Enterprise Value-to-EBITDA (EV/EBITDA) is 11.0. Peer comparison data (industry averages) is not available in the provided inputs to contextualize these multiples. The valuation appears to reflect the company's profitable growth, strong margins, and debt-free balance sheet.
PE
16.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 9x~66x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
11.0x
Enterprise Value Multiple
Investment Risk Disclosure
United Therapeutics faces several key risks. Financially, the primary concern is valuation; the stock trades at a forward P/E of 17.4 and a P/S of 6.8, which are elevated and could compress if growth slows or sentiment shifts. The high short ratio of 5.64 signals significant skepticism in the market, potentially leading to volatility. Operationally, the company is heavily reliant on its PAH franchise, particularly Tyvaso DPI, creating revenue concentration risk. Future growth is largely tied to the successful FDA filing and approval for Tyvaso's new lung disease indication, a process subject to regulatory uncertainty and potential delays. Furthermore, the stock's technical position near its 52-week high after a 33.7% six-month surge increases its vulnerability to a pullback or profit-taking, especially in a broader market that has been weak (S&P 500 down over the same periods).
FAQ
The key risks include: 1) Valuation Risk: High multiples could compress if growth disappoints. 2) Regulatory/Commercial Risk: Future growth hinges on FDA approval and successful launch of Tyvaso for a new indication. 3) Concentration Risk: Revenue is heavily dependent on the Tyvaso franchise and the U.S. market. 4) Sentiment Risk: A high short ratio of 5.64 indicates bearish bets, which can fuel volatility. 5) Technical Risk: Trading near 52-week highs after a major run increases susceptibility to a correction.
The 12-month outlook is mixed with a neutral base case. The bull case (30% probability) sees the stock reaching $607-$700 on successful Tyvaso approval and launch. The base case (50% probability) envisions consolidation in the $540-$607 range as the company executes steadily. The bear case (20% probability) could see a pullback to $450-$540 on regulatory delays or commercial setbacks. The consensus among analysts is positive, with multiple firms maintaining Buy ratings, driven by the Tyvaso catalyst.
UTHR appears fully valued or slightly overvalued based on traditional metrics, though justified by its quality. With a trailing P/E of 16.2 and forward P/E of 17.4, it is not cheap. The P/S ratio of 6.8 and EV/EBITDA of 11.0 also indicate a premium valuation. This premium reflects the company's exceptional profitability (net margin of 41.9%), strong growth profile, and debt-free status. The valuation is sustainable only if the Tyvaso catalyst delivers significant future revenue.
UTHR is a fundamentally strong company, but its attractiveness as a buy at current levels is tempered. The stock has surged 33.7% in six months and 17.7% in one month, pushing it to just 2.5% below its 52-week high. While its debt-free balance sheet, 46% net margin, and positive Phase 3 data for Tyvaso are compelling, the forward P/E of 17.4 and P/S of 6.8 suggest much of the good news is priced in. It may be prudent for new investors to wait for a pullback.
UTHR is more suitable for a long-term investment horizon. The company's strong financial foundation (zero debt, high cash flow) supports durable value. However, the stock's near-term trajectory is highly event-driven, centered on the FDA process for Tyvaso, which introduces significant short-term volatility. Long-term investors can better weather this volatility and benefit from the company's underlying growth in the PAH market and potential pipeline successes. Short-term traders face high uncertainty around a binary regulatory outcome.